Tissue factor pathway inhibitor: Structure-function

Frontiers in Bioscience

Volumn 17, Issue 1, 2012, Pages 262-280

  Broze, George J ^a   Girard, Thomas J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation; Kunitz; Tissue factor pathway inhibitor

Indexed keywords

MUS;

EID: 84860303349     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3926     Document Type: Article

References (174)

1. L. Loeb, M. S. Fleisher and L. Tuttle: The interaction between blood serum and tissue extract in the coagulation of the blood: I. The combined action of serum and tissue extract on fluoride, hirudin, and peptone plasma; the effect of heating on the serum. J Biol Chem 51, 461-483 (1922)
2. L. Loeb, M. S. Fleisher and L. Tuttle: The interaction between blood serum and tissue extract in the coagulation of blood: II. A comparison between the effects of the stroma of erythrocytes and of tissue extracts, unheated and heated, on the coagulation of the blood, and on the mechanism of the interaction of these substances with blood serum. J Biol Chem 51, 485-506 (1922)
3. L. Thomas: Studies on the intravascular thromboplastin effect of tissue suspensions in mice: II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp 81, 26-42 (1947)
4. C. L. Schneider: The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am J Physiol 149, 123-129 (1947)
5. F. D. Mann and M. Hurn: Inactivation of thromboplastin by serum. Fed Proc 8, 105 (1949)
6. R. I. McClaughry: The specificity of anti-thromboplastin activity. J Miss State Med Assoc 49, 685 (1950)
7. W. A. Lanchantin GF: Identification of a thromboplastin inhibitor in serum and in plasma. J Clin Invest 32, 381-389. (1953)
8. C. G. Berry: The degeneration of brain thromboplastin in the presence of normal serum. J Clin Pathol 10, 342-345 (1957)
9. F. Hermansky and J. Vitek: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia 16, 455-456 ( 1960)
10. P. F. Hjort: Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest 9, suppl. 27, 1-182 (1957)
11. S. D. Carson: Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor. FEBS Lett 132, 37-40 (1981) (Pubitemid 12248550)
12. P. E. Dahl, U. Abildgaard, M. L. Larsen, L. Tjensvoll: Inhibition of activated coagulation factor VII by normal human plasma. Thromb Haemost 48, 253-256 (1982) (Pubitemid 13209586)
13. S. A. Morrison and J. Jesty: Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 63, 1338-1347 (1984) (Pubitemid 14120378)
14. N. L. Sanders, S. P. Bajaj, A. Zivelin and S. I. Rapaport: Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 66, 204-212 (1985) (Pubitemid 15004805)
15. A. R. Hubbard and C. A. Jennings: Inhibition of tissue thromboplastin-mediated blood coagulation. Thromb Res 42, 489-498 (1986) (Pubitemid 16073471)
16. G. J. Broze, Jr. and J. P. Miletich: Characterization of the inhibition of tissue factor in serum. Blood 69, 150-155 (1987) (Pubitemid 17007090)
17. L. V. Rao and S. I. Rapaport: Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69, 645-651 (1987) (Pubitemid 17022042)
18. A. R. Hubbard and C. A. Jennings: Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb Res 46, 527-537 (1987) (Pubitemid 17096467)
19. G. J. Broze, Jr, L. A. Warren, W. F. Novotny, D. A. Higuchi, T. L. Girard and J. P. Miletich: The lipoproteinassociated coagulation inhibitor that inhibits the factor VIItissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71, 335-343 (1988) (Pubitemid 18089519)
20. G. J. Broze, Jr., T. J. Girard and W. F. Novotny: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29, 7539-7546 (1990) (Pubitemid 20279168)
21. G. J. Broze, Jr. and J. P. Miletich: Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc Natl Acad Sci U S A 84, 1886-1890 (1987) (Pubitemid 17054118)
22. T. C. Wun, K. K. Kretzmer, T. J. Girard, J. P. Miletich and G. J. Broze, Jr.: Cloning and characterization of a cDNA coding for the lipoprotein- associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263, 6001-6004 (1988)
23. T. J. Girard, R. Eddy, R. L. Wesselschmidt, L. A. MacPhail, K. M. Likert, M. G. Byers, T. B. Shows and G. J. Broze, Jr.: Structure of the human lipoprotein-associated coagulation inhibitor gene. Intron/exon gene organization and localization of the gene to chromosome 2. J Biol Chem 266, 5036-5041 (1991) (Pubitemid 21909457)
24. C. P. van der Logt, P. H. Reitsma and R. M. Bertina: Intron-exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor: the factor Xa dependent inhibitor of the extrinsic pathway of coagulation. Biochemistry 30, 1571-1577 (1991)
25. J. Y. Chang, D. M. Monroe, J. A. Oliver and H. R. Roberts: TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 81, 45-49 (1999) (Pubitemid 29041648)
26. J. Zhang, O. Piro, L. Lu and G. J. Broze, Jr.: Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 108, 623-627 (2003) (Pubitemid 36961180)
27. W. F. Novotny, T. J. Girard, J. P. Miletich and G. J. Broze, Jr.: Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264, 18832-18837 (1989) (Pubitemid 19277636)
28. W. F. Novotny, M. Palmier, T. C. Wun, G. J. Broze, Jr. and J. P. Miletich: Purification and properties of heparinreleasable lipoprotein- associated coagulation inhibitor. Blood 78, 394-400 (1991)
29. O. Piro and G. J. Broze, Jr.: Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 110, 3567-3572 (2004) (Pubitemid 39612572)
30. O. Piro and G. J. Broze, Jr.: Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost 3, 2677-2683 (2005)
31. S. A. Maroney, A. C. Cunningham, J. Ferrel, R. Hu, S. Haberichter, C. M. Mansbach, R. A. Brodsky, D. J. Dietzen and A. E. Mast: A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 4, 1114-1124 (2006)
32. L. F. Lareau, R. E. Green, R. S. Bhatnagar and S. E. Brenner: The evolving roles of alternative splicing. Curr Opin Struct Biol 14, 273-282 (2004) (Pubitemid 38749054)
33. Y. Mori, T. Hamuro, T. Nakashima, T. Hamamoto, S. Natsuka, S. Hase and S. Iwanaga: Biochemical characterization of plasma-derived tissue factor pathway inhibitor: post-translational modification of free, full-length form with particular reference to the sugar chain. J Thromb Haemost 7, 111-120 (2009)
34. P. Colburn and V. Buonassisi: Identification of an endothelial cell product as an inhibitor of tissue factor activity. In vitro Cell Dev Biol 24, 1133-1136 (1988)
35. B. J. Warn-Cramer, S. L. Maki and S. I. Rapaport: A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb Res 61, 515-527 (1991)
36. P. L. Smith, T. P. Skelton, D. Fiete, S. M. Dharmesh, M. C. Beranek, L. MacPhail, G. J. Broze, Jr. and J. U. Baenziger: The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1, 2 Mana alpha. J Biol Chem 267, 19140-19146 (1992)
37. T. J. Girard, D. McCourt, W. F. Novotny, L. A. MacPhail, K. M. Likert and G. J. Broze, Jr.: Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2. Biochem J 270, 621-625 (1990)
38. J. A. Diaz-Collier, M. O. Palmier, K. K. Kretzmer, B. F. Bishop, R. G. Combs, M. G. Obukowicz, R. B. Frazier, G. S. Bild, W. D. Joy, S. R. Hill, K. L. Duffin, M. E. Gustafson, K. D. Junger, R. W. Grabner, G. R. Galluppi and T. C. Wun.: Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 71, 339-346 (1994) (Pubitemid 24083745)
39. W. Gebhard, H. Tschesche and H. Fritz: Biochemistry of aprotinin and aprotinin-like inhibitors. In: Barrett AJ, Salvesen G, eds. Protease Inhibitors. Amsterdam: Elsevier Science, 1986. Pages 375-388.
40. T. J. Girard, L. A. Warren, W. F. Novotny, K. M. Likert, S. G. Brown, J. P. Miletich and G. J. Broze, Jr.: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (1989) (Pubitemid 19107996)
41. L. C. Petersen, S. E. Bjorn, O. H. Olsen, O. Nordfang, F. Norris and K. Norris: Inhibitory properties of separate recombinant Kunitz-type-protease- inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 235, 310-316 (1996) (Pubitemid 26048630)
42. K. D. Berndt, J. Beunink, W. Schroder and K. Wuthrich: Designed replacement of an internal hydration water molecule in BPTI: structural and functional implications of a glycine-to-serine mutation. Biochemistry 32, 4564-4570 (1993) (Pubitemid 23143244)
43. L. C. Petersen, S. E. Bjorn and O. Nordfang: Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 67, 537-541 (1992)
44. T. Hamamoto and W. Kisiel: Full-length human tissue factor pathway inhibitor inhibits human activated protein C in the presence of heparin. Thromb Res 80, 291-297 (1995)
45. M. S. Bajaj, M. N. Kuppuswamy, A. N. Manepalli and S. P. Bajaj: Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 82, 1047-1052 (1999) (Pubitemid 29419717)
46. R. W. Werling, L. R. Zacharski, W. Kisiel, S. P. Bajaj, V. A. Memoli and S. M. Rousseau: Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 69, 366-369 (1993) (Pubitemid 23103124)
47. B. Osterud, M. S. Bajaj and S. P. Bajaj: Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 73, 873-875 (1995)
48. H. Yamabe, H. Osawa, H. Inuma, M. Kaizuka, N. Tamura, S. Tsunoda, Y. Fujita, K. Shirato and K. Onodera: Tissue factor pathway inhibitor production by human mesangial cells in culture. Thromb Haemost 76, 215-219 (1996) (Pubitemid 26285254)
49. N. M. Caplice, C. S. Mueske, L. S. Kleppe, T. E. Peterson, G. J. Broze, Jr. and R. D. Simari: Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 83, 1264-1270 (1998) (Pubitemid 29006041)
50. U. R. Pendurthi, L. V. Rao, J. T. Williams and S. Idell: Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. Blood 94, 579-586 (1999) (Pubitemid 29323872)
51. M. S. Bajaj, S. Steer, M. N. Kuppuswamy, W. Kisiel and S. P. Bajaj: Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells and cardiac myocytes. Thromb Haemost 82, 1663-1672 (1999)
52. P. Nguyen, M. Broussas, P. Cornillet-Lefebvre and G. Potron: Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide. Transfusion 39, 975-982 (1999) (Pubitemid 29439794)
53. J. Crawley, F. Lupu, A. D. Westmuckett, N. J. Severs, V. V. Kakkar and C. Lupu: Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 20, 1362-1373 (2000) (Pubitemid 30262940)
54. A. Kereveur, K. Enjyoji, K. Masuda, C. Yutani and H. Kato: Production of tissue factor pathway inhibitor in cardiomyocytes and its upregulation by interleukin-1. Thromb Haemost 86, 1314-1319 (2001) (Pubitemid 33064584)
55. H. Kothari, G. Kaur, S. Sahoo, S. Idell, L. V. Rao and U. Pendurthi: Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells. J Thromb Haemost 7, 121-131 (2009)
56. A. Dahm, A. Van Hylckama Vlieg, B. Bendz, F. Rosendaal, R. M. Bertina and P. M. Sandset: Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101, 4387-4392 (2003) (Pubitemid 36857803)
57. P. Lesnik, A. Vonica, M. Guerin, M. Moreau and M. J. Chapman: Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 13, 1066-1075 (1993) (Pubitemid 23195809)
58. P. M. Sandset, H. Lund, J. Norseth, U. Abildgaard and L. Ose: Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 11, 138-145 (1991)
59. J. B. Hansen, N. E. Huseby, P. M. Sandset, B. Svensson, V. Lyngmo and A. Nordoy: Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14, 223-229 (1994)
60. T. Abumiya, S. Nakamura, A. Takenaka, O. Takenaka, Y. Yoshikuni, S. Miyamoto, T. Kimura, K. Enjyoji and H. Kato: Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb 14, 483-488 (1994)
61. J. B. Hansen, K. R. Huseby, N. E. Huseby, P. M. Sandset, T. A. Hanssen and A. Nordoy: Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 15, 879-885 (1995)
62. W. F. Novotny, S. G. Brown, J. P. Miletich, D. J. Rader and G. J. Broze, Jr.: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78, 387-393 (1991)
63. G. J. Broze, Jr., G. W. Lange, K. L. Duffin and L. MacPhail: Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 5, 551-559 (1994) (Pubitemid 24301576)
64. T. Kokawa, T. Abumiya, T. Kimura, M. Harada-Shiba, H. Koh, M. Tsushima, A. Yamamoto and H. Kato: Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 15, 504-510 (1995)
65. T. Abumiya, K. Enjyoji, T. Kokawa, Y. Kamikubo and H. Kato: An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 118, 178-182 (1995)
66. N. Ohkura, K. Enjyoji, Y. Kamikubo and H. Kato: A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 90, 1883-1892 (1997) (Pubitemid 27377298)
67. A. Li and T. C. Wun: Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 80, 423-427 (1998) (Pubitemid 28438737)
68. P. G. Stalboerger, C. J. Panetta, R. D. Simari and N. M. Caplice: Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost 86, 923-928 (2001) (Pubitemid 32834206)
69. D. A. Higuchi, T. C. Wun, K. M. Likert and G. J. Broze, Jr.: The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 79, 1712-1719 (1992)
70. I. Salemink, J. Franssen, G. M. Willems, H. C. Hemker, A. Li, T. C. Wun and T. Lindhout: Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 80, 273-280 (1998) (Pubitemid 28393623)
71. A. A. Belaaouaj, A. Li, T. C. Wun, H. G. Welgus and S. D. Shapiro: Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 275, 27123-27128 (2000)
72. T. H. Yun, J. E. Cott, R. I. Tapping, J. M. Slauch and J. H. Morrissey: Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins. Blood 113, 1139-1148 (2009)
73. I. Ott, V. Malcouvier, A. Schomig and F. J. Neumann: Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. Circulation 105, 279-281 (2002) (Pubitemid 34106171)
74. H. Tang, L. Ivanciu, N. Popescu, G. Peer, E. Hack, C. Lupu, F. B. Taylor, Jr. and F. Lupu: Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol 171, 1066-1077 (2007) (Pubitemid 47441003)
75. S. Massberg, L. Grahl, M. L. von Bruehl, D. Manukyan, S. Pfeiler, C. Goosmann, V. Brinkmann, M. Lorenz, K. Bidzhekov, A. B. Khandagale, I. Konrad, E. Kennerknecht, K. Reges, S. Holdenrieder, S. Braun, C. Reinhardt, M. Spannagl, K. T. Preissner and B. Engelmann: Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16, 887-896 (2010)
76. C. Duckers, P. Simioni, L. Spiezia, C. Radu, S. Gavasso, J. Rosing and E. Castoldi: Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 112, 3615-3623 (2008)
77. E. Castoldi, P. Simioni, D. Tormene, J. Rosing and T. M. Hackeng: Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 8, 294-300 (2009)
78. A. E. Dahm, P. M. Sandset and F. R. Rosendaal: The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 6, 393-395 (2008)
79. A. E. Dahm, I. D. Bezemer, P. M. Sandset and F. R. Rosendaal: Interaction between tissue factor pathway inhibitor and factor V levels on the risk of thrombosis. J Thromb Haemost 8, 1130-1132 (2010)
80. M. J. Heeb, D. Prashun, J. H. Griffin and B. N. Bouma: Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J 23, 2244-2253 (2009)
81. M. Ndonwi, E. A. Tuley and Broze GJ Jr. : The Kunitz-3 domain of TFPIα is required for protein S-dependent enhancement of factor Xa inhibition. Blood 116, 1344-1351 (2010)
82. W. F. Novotny, T. J. Girard, J. P. Miletich and G. J. Broze, Jr.: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72, 2020-2025 (1988) (Pubitemid 19030892)
83. S. A. Maroney, S. L. Haberichter, P. Friese, M. L. Collins, J. P. Ferrel, G. L. Dale and A. E. Mast: Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 109, 1931-1937 (2007) (Pubitemid 46348189)
84. S. A. Smith, N. J. Mutch, D. Baskar, P. Rohloff, R. Docampo and J. H. Morrissey: Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 103, 903-908 (2006) (Pubitemid 43212194)
85. S. A. Smith, S. H. Choi, R. Davis-Harrison, J. Huyck, J. Boettcher, C. M. Rienstra and J. H. Morrissey: Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116, 4353-4359 (2010)
86. M. O. Palmier, L. J. Hall, C. M. Reisch, M. K. Baldwin, A. G. Wilson and T. C. Wun: Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 68, 33-36 (1992)
87. S. Valentin, O. Nordfang, C. Bregengard, P. Wildgoose: Evidence that the C terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coagul Fibrinolysis 47, 713-720 (1993) (Pubitemid 23343394)
88. I. Warshawsky, G. J. Broze, Jr. and A. L. Schwartz: The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 91, 6664-6668 (1994) (Pubitemid 24200722)
89. I. Warshawsky, G. Bu, A. Mast, J. E. Saffitz, G. J. Broze, Jr. and A. L. Schwartz: The carboxyterminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 95, 1773-1781 (1995)
90. M. Narita, G. Bu, G. M. Olins, D. A. Higuchi, J. Herz, G. J. Broze, Jr. and A. L. Schwartz: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 270, 24800-24804 (1995)
91. I. Warshawsky, J. Herz, G. J. Broze, Jr. and A. L. Schwartz: The low density lipoprotein receptor related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 271, 25873-25879 (1996) (Pubitemid 26347418)
92. S. Valentin and I. Schousboe: Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemost 75, 796-800 (1996) (Pubitemid 26181856)
93. T. Kojima, A. Katsumi, T. Yamazaki, T. Muramatsu, T. Nagasaka, K. Ohsumi and H. Saito: Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J Biol Chem 271, 5914-5920 (1996) (Pubitemid 26084457)
94. A. E. Mast, D. A. Higuchi, Z. F. Huang, I Warshawsky, A. L. Schwartz and G. J. Broze, Jr.: Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 327, 577-583 (1997) (Pubitemid 27477839)
95. A. Hamik, H. Setiadi, G. Bu, R. P. McEver and J. H. Morrissey: Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 274, 4962-4969 (1999)
96. G. Ho, M. Narita, G. J. Broze, Jr. and A. L. Schwartz: Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: implications for catabolism in vitro and in vivo. Blood 95, 1973-1978 (2000) (Pubitemid 30151634)
97. J. R. Sevinsky, L. V. Rao and W. Ruf: Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factordependent coagulation pathway. J Cell Biol 133, 293-304 (1996) (Pubitemid 26131614)
98. C. Lupu, C. A. Goodwin, A. D. Westmuckett, J. J. Emeis, M. F. Scully, V. V. Kakkar and F. Lupu: Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol 17, 2964-2974 (1997) (Pubitemid 28016049)
99. I. Ott, Y. Miyagi, K. Miyazaki, M. J. Heeb, B. M. Mueller, L. V. Rao and W. Ruf: Reversible regulation of tissue factorinduced coagulation by glycosyl phosphatidylinositolanchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol, 20, 874-882 (2000) (Pubitemid 30151706)
100. A. E. Mast, N. Acharya, M. J. Malecha, C. L. Hall and D. J. Dietzen: Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol 22, 2099-2104 (2002) (Pubitemid 36025221)
101. C. Lupu, X. Hu and F. Lupu: Caveolin-1 enhances tissue factor pathway inhibitor exposure and function on the cell surface. J Biol Chem 280, 22308-22317 (2005) (Pubitemid 40827887)
102. J. Ahamed, M. Belting and W. Ruf: Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105, 2384-2391 (2005) (Pubitemid 40387035)
103. D. J. Dietzen, G. G. Jack, K. L. Page, T. A. Tetzloff, C. L. Hall and A. E. Mast: Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thromb Haemost 89, 65-73 (2003) (Pubitemid 36149794)
104. C. Lupu, F. Lupu, U. Dennehy, V. V. Kakkar and M. F. Scully: Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 15, 2055-2062 (1995)
105. C. Lupu, E. Poulsen, S. Roquefeuil, A. D. Westmuckett, V. V. Kakkar and F. Lupu: Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 19, 2251-2262 (1999) (Pubitemid 29422260)
106. J. B. Hansen, B. Svensson, R. Olsen, M. Ezban, B. Osterud and R. H. Paulssen: Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 83, 937-943 (2000) (Pubitemid 30411697)
107. E. F. Grabowski, D. B. Zuckerman and Y. Nemerson: The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 81, 3265-3270 (1993) (Pubitemid 23172908)
108. A. D. Westmuckett, C. Lupu, S. Roquefeuil, T. Krausz, V. V. Kakkar and F. Lupu: Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 20, 2474-2482 (2000)
109. P. M. Sandset, U. Abildgaard and M. L. Larsen: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50, 803-813 (1988)
110. B. Naumnik, A. Rydzewska-Rosolowska and M. Mysliwiec: Different Effects of Enoxaparin, Nadroparin, and Dalteparin on Plasma TFPI During Hemodialysis: A Prospective Crossover Randomized Study. Clin Appl Thromb Hemost epub, Aug. 3 (2010)
111. J. M. Walenga, W. P. Jeske, M. M. Samama, F. X. Frapaise, R. L. Bick and J. Fareed: Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 11, 397-407 (2002) (Pubitemid 34213393)
112. J. B. Hansen, P. M. Sandset, K. R. Huseby, N. E. Huseby and A. Nordoy: Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 76, 703-709 (1996) (Pubitemid 26388173)
113. J. B. Hansen and P. M. Sandset: Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Thromb Res 91, 177-181 (1998) (Pubitemid 28429586)
114. B. Bendz, J. B. Hansen, T. O. Andersen, P. Ostergaard and P. M. Sandset: Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. Br J Haematol 107, 756-762 (1999) (Pubitemid 30020146)
115. D. Gailani and G. J. Broze, Jr.: Factor XI activation in a revised model of blood coagulation. Science 253, 909-912 (1991) (Pubitemid 21917236)
116. C. van 't Veer and K. G. Mann: Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272, 4367-4377 (1997) (Pubitemid 27078512)
117. M. P. McGee and L. C. Li: Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages. J Biol Chem 266, 8079-8085 (1991) (Pubitemid 21906478)
118. G. J. Broze, Jr., L. A. Warren, J. J. Girard and J. P. Miletich: Isolation of the lipoprotein associated coagulation inhibitor produced by HepG2 (human hepatoma) cells using bovine factor Xa affinity chromatography. Thromb Res 48, 253-259 (1987)
119. R. Wesselschmidt, K. Likert, T Girard, T. C. Wun and G. J. Broze, Jr.: Tissue factor pathway inhibitor: the carboxyterminus is required for optimal inhibition of factor Xa. Blood 79, 2004-2010 (1992)
120. R. Wesselschmidt, K. Likert, Z. Huang, L. MacPhail and G. J. Broze, Jr.: Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 4, 661-669 (1993) (Pubitemid 23343388)
121. T. Lindhout, J. Franssen and G. Willems: Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 74, 910-915 (1995)
122. Z. F. Huang, T. C. Wun and G. J. Broze, Jr.: Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 268, 26950-26955 (1993) (Pubitemid 24006403)
123. J. Jesty, T. C. Wun and A. Lorenz: Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 33, 12686-12694 (1994) (Pubitemid 24345901)
124. H. H. Chen, C. P. Vicente, L. He, D. M. Tollefsen and T. C. Wun: Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood 105, 3902-3909 (2005) (Pubitemid 40656135)
125. T. M. Hackeng, K. M. Sere, G. Tans and J. Rosing: Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103, 3106-3111 (2006) (Pubitemid 43346432)
126. S. Yegneswaran, T. M. Hackeng, P. E. Dawson and J. H. Griffin: The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. J Biol Chem 283, 33046-33052 (2008)
127. A. E. Mast and G. J. Broze, Jr.: Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 87, 1845-1850 (1996) (Pubitemid 26068899)
128. K. Enjyoji, T. Miyata, Y. Kamikubo and H. Kato: Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 34, 5725-5735 (1995)
129. S. Valentin, A. Larnkjer, P. Ostergaard, J. I. Nielsen and O. Nordfang: Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 75, 173-183 (1994) (Pubitemid 24240506)
130. R. J. Baugh, G. J. Broze, Jr. and S. Krishnaswamy: Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 273, 4378-4386 (1998) (Pubitemid 28103174)
131. M. Ndonwi and G. Broze, Jr.: Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 6, 1044-1046 (2008) (Pubitemid 351689932)
132. B. J. Warn-Cramer, L. V. Rao, S. L. Maki and S. I. Rapaport: Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 60, 453-456 (1988) (Pubitemid 19023740)
133. L. V. Rao and W. Ruf: Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor-VIIa with Xa-tissue factor pathway inhibitor. Biochemistry 34, 10867-10871 (1995)
134. T. Hamamoto and W. Kisiel: The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 7, 470-476 (1996) (Pubitemid 26291521)
135. T. Hamamoto, M. Yamamoto, O. Nordfang, J. G. Petersen, D. C. Foster and W. Kisiel: Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitztype domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 268, 8704-8710 (1993) (Pubitemid 23118657)
136. S. Valentin, C. P. Reutlingsperger, O. Nordfang and T. Lindhout: Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: A comparison between tissue factor pathway inhibitor and inactive factor VIIa. Thromb Haemost 74, 1478-1485 (1995) (Pubitemid 26018665)
137. A. H. Pedersen, O. Nordfang, F. Norris, F. C. Wiberg, P. M. Christensen, K. B. Moeller, J. Meidahl-Pedersen, T. C. Beck, K. Norris and U. Hedner: Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factorinitiated coagulation reactions. J Biol Chem 265, 16786-16793 (1990) (Pubitemid 120013485)
138. N. S. Callander, L. V. Rao, O. Nordfang, P. M. Sandset, B. Warn-Cramer and S. I. Rapaport: Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J Biol Chem, 267, 876-882 (1992)
139. K. M. Sere, J. Rosing and T. M. Hackeng: Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. Blood 104, 3624-3630 (2005) (Pubitemid 39564437)
140. T. M. Hackeng and J. Rosing: Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 29, 2015-2020 (2009)
141. L. F. A. Maurissen, E. Castoldi, P. Simioni, J. Rosing and T. M. Hackeng: Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 8, 750-758 (2010)
142. A. E. Dahm, T. O. Andersen, F. Rosendaal and P. M. Sandset: A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 3, 651-658 (2005) (Pubitemid 41647875)
143. P. M. Sandset, M. L. Larsen, U. Abildgaard, A. K. Lindahl and O. R. Odegaard: Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 2, 425-433 (1991)
144. T. A. Drake, J. Cheng, A. Chang and F. B. Taylor, Jr.: Expression of tissue factor, thrombomodulin, and Eselectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142, 1458-1470 (1993) (Pubitemid 24058133)
145. C. Lupu, A. D. Westmuckett, G. Peer, L. Ivanciu, H. Zhu, F. B. Taylor and F. Lupu: Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol 167, 1161-1172 ( 2005) (Pubitemid 41416266)
146. A. Solovey, R. Kollander, A. Shet, L. C. Milbauer, S. Choong, A. Panoskaltsis-Mortari, B. R. Blazar, R. J. Kelm, Jr. and R. P. Hebbel: Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 104, 840-846 ( 2004) (Pubitemid 38970583)
147. J. Contrino, G. Hair, D. L. Kreutzer and F. R. Rickles: In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2, 209-215 (1996) (Pubitemid 26054985)
148. M. Shoji, W. W. Hancock, K. Abe, C. Micko, K. A. Casper, R. M. Baine, J. N. Wilcox, I. Danave, D. L. Dillehay, E. Matthews, J. Contrino, J. H. Morrissey, S. Gordon, T. S. Edgington, B. Kudryk, D. L. Kreutzer and F. R. Rickles: Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152, 399-411 (1998) (Pubitemid 28106386)
149. D. Muller, E. M. Mervaala, R. Dechend, A. Fiebeler, J. K. Park, F. Schmidt, J. Theuer, V. Breu, N. Mackman, T. Luther, W. Schneider, D. Gulba, D. Ganten, H. Haller and F. C. Luft: Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 157, 111-122 (2000) (Pubitemid 30641729)
150. H. Holschermann, R. M. Bohle, H. Zeller, Schmidt H, U. Stahl, L. Fink, H. Grimm, H. Tillmanns and W. Haberbosch: In situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy. Am J Pathol 154, 211-220 (1999) (Pubitemid 29031628)
151. M. Usui, N. Kuriyama, M. Kisawada, T. Hamada, S. Mizuno, H. Sakurai, M. Tabata, H. Imai, K. Okamoto, S. Uemoto and S. Isaji: Tissue factor expression demonstrates severe sinusoidal endothelial cell damage during rejection after living-donor liver transplantation. J Hepatobiliary Pancreat Surg 16, 513-520 (2009)
152. L. More, R. Sim, M. Hudson, A. P. Dhillon, R. Pounder and A. J. Wakefield: Immunohistochemical study of tissue factor expression in normal intestine and idiopathic inflammatory bowel disease. J Clin Patho 46, 703-708 (1993) (Pubitemid 23242418)
153. P. S. Bora, Z. Hu, T. H. Tezel, J. H. Sohn, S. G. Kang, J. M. Cruz, N. S. Bora, A. Garen and H. J. Kaplan: Immunotherapy for choroidal neovascularization in a laserinduced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci USA 100, 2679-2684 (2003) (Pubitemid 36297558)
154. G. Krikun, Z. Hu, K. Osteen, K. L. Bruner-Tran, F. Schatz, H. S. Taylor, P. Toti, F. Arcuri, W. Konigsberg, A. Garen, C. J. Booth and C. J. Lockwood: The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol 176, 1050-1056. (2010)
155. J. Zhou, L. May, P. Liao, P. L. Gross and J. I. Weitz: Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol 29, 863-869 ( 2009)
156. B. T. Atkinson, R. Jasuja, V. Chen, P. Nandivada, B. Furie and B. C. Furie: Laser-induced endothelial cell activation supports fibrin formation. Blood 116, 4675-4683 (2010)
157. S. A. Maroney, J. P. Ferrel, M. L. Collins and A. E. Mast: TFPIgamma is an active alternatively spliced form of TFPI present in mice but not in humans. J Thromb Haemost 6:1344-1351 (2008)
158. S. A. Maroney, J. P. Ferrel, S. Pan, T. A. White, R. D. Simari, J. H. McVey and A. E. Mast: Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost 7, 1106-1113 (2009)
159. Z. F. Huang, D. Higuchi, N. Lasky and G. J. Broze, Jr.: Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90, 944-951 (1997) (Pubitemid 27314126)
160. Y. F. Lin, N. Zhang, H. S. Guo, D. S. Kong, T. Jiang, W. Liang, Z. H. Zhao, Q. Q. Tang and D. Ma: Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis 12, 2163-2173 (2007) (Pubitemid 350077250)
161. W. Liang, J. Cheng, R. Liu, J. P. Wang, J. G. Mu, Q. H. Wang, H. J. Wang and D. Ma: Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides 30, 2330-2336 (2009)
162. S. Schirm, X. Liu, L. L. Jennings, P. Jedrzejewski, Y. Dai and S. Hardy: Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 199, 1807-1815 (2009)
163. P. Papareddy, M. Kalle, G. Kasetty, M. Morgelin, V. Rydengard, B. Albiger, K. Lundqvist, M. Malmsten and A. Schmidtchen: C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 285, 28387-28398 (2010)
164. F. E. Van Den Boogaard, X. Brands, M. J. Schultz, M. Levi, J. J. Roelofs, C. van't Veer and T. van der Poll: Recombinant Human Tissue Factor Pathway Inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 9, 122-132 (2010)
165. J. C. Chan, P. Carmeliet, L. Moons, E. D. Rosen, Z. F. Huang, G. J. Broze, Jr., D. Collen and F. J. Castellino: Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest, 103, 475-482 (1999) (Pubitemid 29094047)
166. B. Pedersen, T. Holscher, Y. Sato, R. Pawlinski and N Mackman: A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105, 2777-2782 (2005) (Pubitemid 40446269)
167. D. T. Eitzman, R. J. Westrick, X. Bi, S. L. Manning, J. E. Wilkinson, G. J. Broze and D. Ginsburg: Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 105, 2139-2142 (2002) (Pubitemid 34517155)
168. S. A. Maroney, B. C. Cooley, R. Sood, H. Weiler and A. E. Mast: Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition. J Thromb Haemost 6, 111-117 (2008)
169. R. J. Westrick, P. F. Bodary, Z. Xu, Y. C. Shen, G. J. Broze, Jr, D. T. Eitzman: Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103, 3044-3046 ( 2001) (Pubitemid 32587848)
170. R. Singh, S. Pan, C. S. Mueske, T. A. Witt, L. S. Kleppe, T. E. Peterson, N. M. Caplice and R. D. Simari: Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodeling. Thromb Haemost 89, 747-751 (2003) (Pubitemid 36456973)
171. S. Pan, L. S. Kleppe, T. A. Witt, C. S. Mueske and R. D. Simari: The effect of vascular smooth muscle celltargeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost 92, 495-502 ( 2004) (Pubitemid 39248006)
172. T. A. White, T. A. Witt, S. Pan, C. S. Mueske, L. S. Kleppe, E. W. Holroyd, H. C. Champion and R. D. Simari: Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 43, 35-45 (2010)
173. S. Pan, T. A. White, T. A. Witt, A. Chiriac, C. S. Mueske and R. D. Simari: Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Circ Res 105, 713-720 (2009)
174. T. A. White, T. Johnson, N. Zarzhevsky, C. Tom, S. Delacroix, E. W. Holroyd, S. A. Maroney, R. Singh, S. Pan, W. P. Fay, J. van Deursen, A. E. Mast, G. S. Sandhu and R. D. Simari: Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis, but is not required for development or hemostasis. Blood 116, 1787-1794 ( 2010)